Search Topic
Project Topics Seminar Topics Login Create Account
PARKLYN
ERVICES
 · RC: 2994849
Paclitaxel Loaded Polylactide-Co-Glycolide Acids for Coronar
WhatsApp

Paclitaxel Loaded Polylactide-Co-Glycolide Acids for Coronary Artery Disease and Cancer Treatment

This page presents an excerpt from the research material, including the preliminary pages, table of contents, abstract, Chapters One to Five, and references. The complete material for Paclitaxel Loaded Polylactide-Co-Glycolide Acids for Coronary Artery Disease and Cancer Treatment covers all sections listed in the table of contents provided by Sparklyn Services and will be sent in Microsoft Word (.docx) format upon request, allowing you to make changes whenever needed.

Material Excerpt on Paclitaxel Loaded Polylactide-Co-Glycolide Acids for Coronary Artery Disease and Cancer Treatment

ABSTRACT

The number one killer disease in the world is Cardiovascular Disease1. The most serious element of Cardiovascular Disease is Coronary Artery Disease. Currently, the main treatment for Coronary Artery Disease is stent placement surgery. However, its long time safety and efficiency are the major setbacks, as it is associated with late restenosis and late thrombosis. These are set caused by the durable polymeric film used as the drug carrier.

To improve on the current treatment (stent placement surgery), a biodegradable drug delivery system was synthesized. Paclitaxel was successfully entrapped into the polylactide-co-glycolide acids microspheres via single solvent microencapsulation evaporation method. Optical Microscopy was used to study the shape and morphology of the microspheres. The particle sizes were found to range of the microspheres is 15. 18 — 40.11µm, with a mean size of 29.415 µm, a p-value 0.986 and a z-value-0.02.

The results suggest that the encapsulated drug loaded microspheres can be used as biodegradable drug eluting structures for localized vascular-targeted therapy for the treatment of coronary artery disease. This is a presented as potential alternative to stent placement surgery. The potential extensions to localized cancer treatment are also elucidated.

CHAPTER ONE

1.0 Introduction and Background of the Study

1.1 Statement of the problem (Heart Disease)

Cardiovascular disease (CVD) is caused by disorders of the heart and blood vessels, which includes coronary heart disease (heart attacks), cerebrovascular disease (stroke), raised blood pressure (hypertension), peripheral artery disease, rheumatic heart disease, congenital heart disease and heart failure [1,2]. The first two are the major killer diseases in the whole world.

In 2002, it was estimated that 29% of deaths worldwide (16.7 million deaths) were due to CVD and that 43% of global morbidity and mortality, measured in disability-adjusted life years (DALYs), and was caused by CVD. Furthermore, 78% of global mortality and 86% of mortality and morbidity from CVD occurs in developing countries.

…

CHAPTER TWO

2.1 Introduction

This chapter presents existing knowledge, relevant theories, previous research findings, and the methods used by other researchers to provide background information on Paclitaxel Loaded Polylactide-Co-Glycolide Acids for Coronary Artery Disease and Cancer Treatment. This section also documents the state of the art on the subject under study and provides a comprehensive review of the existing literature. In this research work the literature review includes the conceputal review, theoretical framework, the review of related literature …

How to Download the Complete PDF Material (Table of Contents, Abstract, Chapter 1-5, and References)

Above is a preview excerpt of the full study on “Paclitaxel Loaded Polylactide-Co-Glycolide Acids for Coronary Artery Disease and Cancer Treatment”. The complete material, including all five chapters, is available for download upon request. Get in touch with us here!